| Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing cell therapies to patients, particularly in solid tumors. Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables Co. to identify cancer targets, find and genetically engineer T-cell receptors, and produce therapeutic candidates for administration to patients. Co. has three SPEAR T-cells in clinical trials, ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4) and ADP-A2AFP (AFP). A fourth SPEAR T-cell, the NY-ESO SPEAR T-cell is Co.'s collaboration with GlaxoSmithKline. We show 1 historical shares outstanding datapoints in our coverage of ADAP's shares outstanding history.|
Understanding the changing numbers of ADAP shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADAP versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADAP by allowing them to research ADAP shares outstanding history
as well as any other stock in our coverage universe.